CJC-1295 with DAC

CJC-1295 with DAC Research Peptide
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses

CJC-1295 with DAC (DAC:GRF, CAS 446262-90-4) is a synthetic 30 amino acid GHRH analog incorporating ConjuChem Biotechnologies’ Drug Affinity Complex (DAC) technology, supplied by Nextday Peptides for laboratory and analytical research applications. The DAC component — a maleimido lysine derivative — is designed to covalently associate with serum albumin in experimental systems, extending the effective half-life of the GHRH analog from approximately 30 minutes (unmodified) to 6–8 days in research models. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.

Compound Specifications

Why Research Laboratories Select CJC-1295 with DAC

CJC-1295 with DAC is the long-acting variant of CJC-1295, distinguished by its DAC-mediated albumin binding that dramatically extends its persistence in experimental systems compared to the No DAC version. Where CJC-1295 No DAC produces short-acting pulsatile GHRH receptor activation lasting 30 minutes to 2 hours, the DAC version maintains sustained GHRH receptor activation for 6–8 days in research models — making it an essential complementary tool for laboratories investigating sustained versus pulsatile GH secretagogue signaling dynamics.

• Drug Affinity Complex (DAC) — maleimido lysine derivative enabling covalent albumin binding at Cys34 of serum albumin
• Extended half-life — approximately 6–8 days in research models versus ~30 minutes for unmodified GHRH analog
• Sustained GHRH receptor activation — useful for studying prolonged GH secretagogue dynamics versus pulsatile CJC-1295 No DAC
• 30 amino acid sequence incorporating four DPP-IV resistant substitutions — enhanced enzymatic stability over native GHRH
• Teichman et al. (2006) published human RCT data in Journal of Clinical Endocrinology & Metabolism — extensive published literature available
• Lyophilized format ensures stability and reproducibility across experimental runs
• Batch and lot identifiers on all labeling for full laboratory documentation compliance

Research Background

CJC-1295 with DAC was developed by ConjuChem Biotechnologies as part of their DAC platform technology. Sam et al. (2004) published pharmacokinetic findings in Endocrinology (PMID: 15817669) demonstrating albumin-mediated half-life extension. Teichman et al. (2006) published landmark human RCT data in the Journal of Clinical Endocrinology & Metabolism showing that a single administration produced sustained GH elevation for multiple days in human subjects. The compound is listed on the World Anti-Doping Agency (WADA) prohibited list alongside other GHRH analogs. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.

Reference sources: Sam et al. (2004) — Endocrinology | Teichman et al. (2006) — Journal of Clinical Endocrinology & Metabolism

Shipping & Fulfillment

• Ships from U.S. warehouses — Florida, North Carolina, and California
• Overnight and 2-day shipping available at checkout
• Same-day processing on orders placed before 3:30 PM ET
• Discreet packaging with full tracking provided
• Bulk research orders welcome — contact us for volume pricing

Storage & Handling

• Store lyophilized peptide at -20°C away from light and moisture
• After reconstitution store at 2–8°C and use promptly
• Avoid repeated freeze-thaw cycles to maintain DAC linker and peptide integrity
• Handle using appropriate laboratory safety protocols
• Keep containers sealed when not in use

Frequently Asked Questions

For Research Use Only — Not for human or veterinary consumption • Not evaluated by the FDA • Supplied by Nextday Peptides for laboratory research applications only